Biovica International AB (publ) (STO:BIOVIC.B)

Market Cap	62.58M
Revenue (ttm)	8.19M
Net Income (ttm)	-106.39M
Shares Out	97.79M
EPS (ttm)	-1.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	81,818
Average Volume	190,782
Open	0.7000
Previous Close	0.6600
Day's Range	0.6100 - 0.7100
52-Week Range	0.5000 - 3.1900
Beta	1.80
RSI	34.23
Earnings Date	Jun 18, 2025

About Biovica International AB

Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the United States of America. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation. It serves cancer institutes, pharmaceutical companies, and collaborative groups. Biovica International AB (publ) was incorporated in 2008 and is headq...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 32
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: BIOVIC.B

Financial Performance

In 2024, Biovica International AB's revenue was 7.30 million, an increase of 39.99% compared to the previous year's 5.21 million. Losses were -124.82 million, 13.0% more than in 2023.